J.C. Reubi et al. / European Journal of Pharmacology 456 (2002) 45–49
49
Otte, A., Mueller-Brand, J., Dellas, S., Nitzsche, E.U., Herrmann, R.,
Maecke, H.R., 1998. Yttrium-90-labelled somatostatin-analogue for
cancer treatment. Lancet 351, 417–418.
nated counterparts (Krenning et al., 1995), the development
of chelator-linked KE108 will be given first priority (Hep-
peler et al., 1999). However, the in vivo characterization of
KE108, such as its in vivo stability, metabolism, biodistri-
bution and toxicology, will represent further necessary steps
before clinical applications will be started.
Paganelli, G., Zoboli, S., Cremonesi, M., Bodei, L., Ferrari, M., Grana, C.,
Bartolomei, M., Orsi, F., De Cicco, C., Macke, H.R., Chinol, M., de
Braud, F., 2001. Receptor-mediated radiotherapy with 90Y-DOTA–D-
Phe1–Tyr3–octreotide. Eur. J. Nucl. Med. 28, 426–434.
Patel, Y., 1999. Somatostatin and its receptor family. Front. Neuroendoc-
rinol. 20, 157–198.
Pfeiffer, M., Koch, T., Schroder, H., Klutzny, M., Kirscht, S., Kreienkamp,
H.J., Hollt, V., Schulz, S., 2001. Homo- and heterodimerization of
somatostatin receptor subtypes. Inactivation of sst(3) receptor function
by heterodimerization with sst(2A). J. Biol. Chem. 276, 14027–14036.
Reubi, J.C., 1995. In vitro identification of vasoactive intestinal peptide
receptors in human tumors: implications for tumor imaging. J. Nucl.
Med. 36, 1846–1853.
Acknowledgements
The authors acknowledge the financial support of the
Swiss National Science Foundation (No. 31-52969.97),
Mallinckrodt Medical, the Commission for Technology and
Innovation (KTI-project 4668.1 EUS) and the COST action
B-12 of the European Community.
Reubi, J.C., Kvols, L.K., Waser, B., Nagorney, D., Heitz, P.U., Charbo-
neau, J.W., Reading, C.C., Moertel, C., 1990. Detection of somatostatin
receptors in surgical and percutaneous needle biopsy samples of carci-
noids and islet cell carcinomas. Cancer Res. 50, 5969–5977.
Reubi, J.C., Schaer, J.C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J.,
Ma¨cke, H.R., 2000a. Affinity profiles for human somatostatin receptor
sst1–sst5 of somatostatin radiotracers selected for scintigraphic and
radiotherapeutic use. Eur. J. Nucl. Med. 27, 273–282.
References
Blum, J., Handmaker, H., Lister-James, J., Rinne, N., 2000. A multicenter
trial with a somatostatin analog 99mTc depreotide in the evaluation of
solitary pulmonary nodules. Chest 117, 1232–1238.
Reubi, J.C., Schaer, J.C., Wenger, S., Hoeger, C., Erchegyi, J., Waser, B.,
Rivier, J., 2000b. sst3-selective potent peptidic somatostatin receptor
antagonists. Proc. Natl. Acad. Sci. U. S. A. 97, 13973–13978.
Reubi, J.C., Waser, B., Schaer, J.C., Laissue, J.A., 2001. Somatostatin
receptor sst1–sst5 expression in normal and neoplastic human tissues
using receptor autoradiography with subtype-selective ligands. Eur. J.
Nucl. Med. 28, 836–846.
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G., 2002.
SOM230: a novel somatostatin peptidomimetic with broad somatotro-
pin release inhibiting factor (SRIF) receptor binding and a unique anti-
secretory profile. Eur. J. Endocrinol. 146, 707–716.
Corleto, V.D., Weber, H.C., Jensen, R.T., 1999. Expression of somatostatin
receptor subtypes on guinea pig gastric and colonic smooth muscle
cells. Am. J. Physiol. 277, G235–G244.
Rocheville, M., Lange, D.C., Kumar, U., Sasi, R., Patel, R.C., Patel, Y.C.,
2000. Subtypes of the somatostatin receptor assemble as functional
homo- and heterodimers. J. Biol. Chem. 275, 7862–7869.
´ ´
Heppeler, A., Froidevaux, S., Ma¨cke, H.R., Jermann, E., Behe, M., Powell,
P., Hennig, M., 1999. Radiometal-labelled macrocyclic chelator-deriva-
tised somatostatin analogue with superb tumour-targeting properties and
potential for receptor-mediated internal radiotherapy. Chem. Eur. J. 5,
1974–1981.
Rohrer, S.P., Birzin, E.T., Mosley, R.T., Berk, S.C., Hutchins, S.M., Shen,
D., Xiong, Y., Hayes, E.C., Parmar, R.M., Foor, F., Mitra, S.W., De-
grado, S.J., Shu, M., Klopp, J.M., Cai, S., Blake, A., Chan, W.W.S.,
Pasternak, A., Yan, L., Patchett, A.A., Smith, R.G., Chapman, K.T.,
Schaeffer, J.M., 1998. Rapid identification of subtype-selective agonists
of the somatostatin receptor through combinatorial chemistry. Science
282, 737–740.
Hoyer, D., Bell, G.I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humphrey,
P.P.A., O’Carroll, A., Patel, Y.C., Schonbrunn, A., Taylor, J.E., Reisine,
T., 1995. Classification and nomenclature of somatostatin receptors.
Trends Pharmacol. Sci. 16, 86–88.
Schaer, J.C., Waser, B., Mengod, G., Reubi, J.C., 1997. Somatostatin re-
ceptor subtypes sst1, sst2, sst3, and sst5 expression in human pituitary,
gastroenteropancreatic and mammary tumors: comparison of mRNA
analysis with receptor autoradiography. Int. J. Cancer 70, 530–537.
Sharma, K., Patel, Y.C., Srikant, C.B., 1996. Subtype-selective induction of
wild-type p53 and apoptosis, but not cell cycle arrest, by human soma-
tostatin receptor 3. Mol. Endocrinol. 10, 1688–1696.
Krenning, E.P., Kwekkeboom, D.J., Pauwels, S., Kvols, L.K., Reubi, J.C.,
1995. Somatostatin Receptor Scintigraphy Raven Press, New York.
Krenning, E.P., Kooij, P.P.M., Pauwels, S., Breeman, W.A., Postema, P.T.,
De Herder, W.W., Valkema, R., Kwekkeboom, D.J., 1996. Somatostatin
receptor: scintigraphy and radionuclide therapy. Digestion 57 (Suppl. 1),
57–61.
Lamberts, S.W., van der Lely, A.J., de Herder, W.W., Hofland, L.J., 1996.
Octreotide. New Engl. J. Med. 334, 246–254.
Traub, T., Petkov, V., Ofluoglu, S., Pangerl, T., Raderer, M., Fueger, B.J.,
Schima, W., Kurtaran, A., Dudczak, R., Virgolini, I., 2001. 111In-DO-
TA-lanreotide scintigraphy in patients with tumors of the lung. J. Nucl.
Med. 42, 1309–1315.
Lebtahi, R., Le Cloirec, J., Houzard, C., Daou, D., Sobhani, I., Sassolas, G.,
Mignon, M., Bourguet, P., Le Guludec, D., 2002. Detection of neuro-
endocrine tumors: (99m)Tc-P829 scintigraphy compared with (111)In-
pentetreotide scintigraphy. J. Nucl. Med. 43, 889–895.
Virgolini, I., Patri, P., Novotny, C., Traub, T., Leimer, M., Fuger, B., Li,
S.R., Angelberger, P., Raderer, M., Wogritsch, S., Kurtaran, A., Kletter,
K., Dudczak, R., 2001. Comparative somatostatin receptor scintigraphy
using in-111-DOTA-lanreotide and in-111-DOTA–Tyr3–octreotide
versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated
radionuclide therapy. Ann. Oncol. 12, S41–S45.
Murthy, K.S., Coy, D.H., Makhlouf, G.M., 1996. Somatostatin receptor-
mediated signaling in smooth muscle. J. Biol. Chem. 271, 23458–23463.
Oberg, K., 1998. Advances in chemotherapy and biotherapy of endocrine
tumors. Curr. Opin. Oncol. 10, 58–65.